| Literature DB >> 29724046 |
Jing Guo1, Minmin Li2,3, Yongguo Liu4, Fengzhong Wang5, Zhiqiang Kong6, Yufeng Sun7, Jia Lu8, Nuo Jin9, Yatao Huang10, Jiameng Liu11, Frédéric Francis12, Bei Fan13.
Abstract
Ultra-performance convergence chromatography is an environmentally-friendly analytical method that uses dramatically reduced amounts of organic solvents. In addition, a robust and highly sensitive chiral separation method was developed for the novel chiral acaricide cyflumetofen by using ultra-performance convergence chromatography coupled with tandem mass spectrometry, which shows that stereoisomer recoveries determined for various apple parts ranged from 78.3% to 119.9%, with the relative standard deviations being lower than 14.0%. The half-lives of (−)-cyflumetofen and (+)-cyflumetofen obtained under 5-fold applied dosage equal to 22.13 and 22.23 days, respectively. For 1.5-fold applied dosage, the respective values were determined as 22.42 and 23.64 days, i.e., the degradation of (−)-cyflumetofen was insignificantly favored over that of its enantiomer. Importantly, cyflumetofen was unevenly distributed in apples, with its relative contents in apple peel, peduncle, and pomace equal to 50%, 22%, and 16%, respectively. The proposed method can be used to efficiently separate and quantify chiral pesticide with advantages of a shorter analysis time, greater sensitivity, and better environmental compatibility. Additionally, the consumption of apples with residue of cyflumetofen did not pose a health risk to the population if the cyflumetofen applied under satisfactory agricultural practices after the long-term dietary risk assessment.Entities:
Keywords: chiral cyflumetofen; dietary risk assessment; distribution; enantioselective degradation; ultra-performance convergence chromatography
Mesh:
Substances:
Year: 2018 PMID: 29724046 PMCID: PMC6099807 DOI: 10.3390/molecules23051060
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1UPCC-MS/MS chromatograms of cyflumetofen enantiomers.
Figure 2Cyflumetofen recoveries in seven studied matrices at three spiking levels.
Uncertainty (Uc) and expanded uncertainty (Uexp) in apple matrices for (−)-cyflumetofen and (+)-cyflumetofen at 50, 500, and 1000 μg/kg.
| Uncertainty | (−)-cyflumetofen | (+)-cyflumetofen |
|---|---|---|
|
| 0.0025 | 0.0025 |
|
| 0.0202 | 0.0305 |
|
| 0.0045 | 0.0038 |
|
| 0.0218 | 0.0293 |
|
| 0.0301 | 0.0425 |
| 6.0 | 8.5 |
Figure 3Degradation of cyflumetofen under field conditions, (A) 1.5-fold applied dosage; (B) 5-fold applied dosage; (C) EF value.
Degradation kinetic constant (k), Half-life (T1/2) and correlation coefficient (R2) values of cyflumetofen in apple.
| Sample | Enantiomer | K × 10−2 (day−1) |
| |
|---|---|---|---|---|
| Apple (1.5-fold dosage) | (−)-cyflumetofen | 4.01 | 22.42a | 0.7938 |
| (+)-cyflumetofen | 3.32 | 23.64a | 0.7662 | |
| Apple (5-fold dosage) | (−)-cyflumetofen | 3.17 | 22.13a | 0.7468 |
| (+)-cyflumetofen | 2.70 | 22.23a | 0.7736 |
Figure 4Distributions of cyflumetofen in apple samples, (A) (−)-cyflumetofen; (B) (+)-cyflumetofen.
Characterization of the population and dietary intake of apples.
| Subpopulation | Age | Average Body Weight (kg) | Consumption of Apples (g·day−1) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Female | Male | Female | Male | ||||||
| Urban | Rural | Urban | Rural | Urban | Rural | Urban | Rural | ||
| Kids | 2–6 | 17.4 | 15.5 | 18.3 | 16.1 | 126.3 | 109.5 | 134.1 | 99.4 |
| Children | 7–13 | 34.1 | 29.4 | 35.3 | 29.6 | 154.9 | 96.6 | 147.0 | 101.4 |
| Teenagers | 14–17 | 51.0 | 47.8 | 56.2 | 50.4 | 209.0 | 108.3 | 177.1 | 91.5 |
| Adults | 18–59 | 56.0 | 54.0 | 65.7 | 60.5 | 162.2 | 84.0 | 118.3 | 73.6 |
| Seniors | ≥60 | 54.9 | 48.8 | 63.7 | 55.9 | 132.8 | 42.3 | 142.6 | 45.9 |
Dietary intake risk assessment of cyflumetofen in whole apple.
| Subpopulation | Age | RQ % | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 1.5-Fold | 5-Fold | ||||||||
| Female | Male | Female | Male | ||||||
| Urban | Rural | Urban | Rural | Urban | Rural | Urban | Rural | ||
| Kids | 2–6 | 0.94 | 0.91 | 0.95 | 0.80 | 4.44 | 4.32 | 4.48 | 3.78 |
| Children | 7–13 | 0.59 | 0.43 | 0.54 | 0.44 | 2.78 | 2.01 | 2.55 | 2.10 |
| Teenagers | 14–17 | 0.53 | 0.29 | 0.41 | 0.23 | 2.51 | 1.39 | 1.93 | 1.11 |
| Adults | 18–59 | 0.37 | 0.20 | 0.23 | 0.16 | 1.77 | 0.95 | 1.10 | 0.74 |
| Seniors | ≥60 | 0.31 | 0.11 | 0.29 | 0.11 | 1.48 | 0.53 | 1.37 | 0.50 |
Figure 5Diagram of analytical procedure including extraction and purification steps.